Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• The participant or their guardian must be willing to sign a written consent form agreeing to take part in the trial.
• Participants must be male or female, aged between 1 and 17 years old (inclusive).
• Participants must have been diagnosed with acute lymphoblastic leukemia (a type of blood cancer) according to World Health Organization standards.
• The leukemia must be in complete remission (meaning no signs of the disease can be detected in the blood) before the transplant takes place.
• A suitable half-matched (haploidentical) family donor must be available, and the participant or guardian must agree to proceed with this type of stem cell transplant.
• Participants must have a general health score of 70 or higher on a standard medical scale, meaning they are able to care for themselves and do normal daily activities.
• Heart function must be within an acceptable range based on a standard medical classification system (confirm with trial site).
• Liver enzyme levels (ALT and AST) must be no more than 2.5 times the normal upper limit, and bilirubin levels no more than 2 times the normal upper limit.
• Kidney function must show creatinine levels no more than 1.5 times the normal upper limit, or the kidneys must be filtering at an adequate rate (at least 60 ml/min).
• Lung function must be acceptable — meaning no significant breathing difficulties, no need for oxygen support, no lung scarring condition, and no active lung infection.

Who may not be able to join:

• People whose leukemia has not gone into complete remission before the transplant.
• People who have chosen a donor who is not a half-matched (haploidentical) family member.
• People with serious heart, liver, kidney, or lung disease that would make it unsafe to go through the pre-transplant treatment process.
• People who have an active infection that is not responding to treatment, or other life-threatening health complications.
• People with a history of another type of cancer, a psychiatric disorder, or HIV infection.
• People whose participant or guardian refuses to sign the consent form, is unwilling to attend required follow-up appointments, or does not agree to their data being used to support future research and medical practice.
• People whom the trial investigator considers unsuitable for any other reason.

Important: Always verify eligibility with the trial site directly before applying.